Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects (TQT)

This study has been completed.
Sponsor:
Collaborator:
Quintiles
Information provided by (Responsible Party):
FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier:
NCT01487135
First received: November 29, 2011
Last updated: October 4, 2013
Last verified: October 2013
  Purpose

The purpose of this study is to evaluate the effect of EVP-6124 at therapeutic and supratherapeutic concentrations on cardiac repolarization in healthy subjects.


Condition Intervention Phase
Healthy Subjects
Cardiac Repolarization
Drug: EVP-6124
Drug: Placebo
Drug: Moxifloxacin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.

Resource links provided by NLM:


Further study details as provided by FORUM Pharmaceuticals Inc:

Primary Outcome Measures:
  • Change-from-baseline in individual corrected QTc (ΔQTcI) for EVP-6124 vs. placebo [ Time Frame: Day 1: predose to 20 hours postdose; Day 2 predose to 168 hours postdose ] [ Designated as safety issue: Yes ]

    Change-from-baseline in Fridericia's correction QTc (ΔQTcF) and change-from-baseline in Bazett's correction QTc (ΔQTcB) will be secondary variables.

    The placebo-corrected baseline-adjusted QTc (ΔΔQTc), calculated as differences between time-matched mean change-from-baseline QTc values obtained on Day 1 (low dose) and on Day 2 (high dose) of the EVP-6124 treatment relative to the corresponding QTc values obtained on Day 1 and Day 2 of the placebo treatment, will be evaluated to quantify the effect of EVP-6124 on cardiac repolarization.



Secondary Outcome Measures:
  • Change-from-baseline in individual corrected QTc (ΔQTcI) for positive control vs. placebo [ Time Frame: Day 1: predose to 20 hours postdose ] [ Designated as safety issue: No ]
    The placebo-corrected baseline-adjusted QTc (ΔΔQTc), calculated as differences between time-matched mean change-from-baseline QTc values obtained on Day 1 of the moxifloxacin treatment relative to QTc values obtained on Day 1 of the placebo treatment, will be evaluated to establish assay sensitivity.

  • Safety and tolerability of EVP-6124 at low dose and high doses [ Time Frame: Day -1 through follow-up (5 to 10 days after discharge) ] [ Designated as safety issue: Yes ]
    All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements.


Enrollment: 60
Study Start Date: December 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EVP-6124 Drug: EVP-6124
A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
Placebo Comparator: Placebo
Cranberry juice (180 mL)
Drug: Placebo
Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
Active Comparator: Moxifloxacin Drug: Moxifloxacin
A moxifloxacin 400 mg tablet administered orally on Day 1
Other Name: Avelox

Detailed Description:

Subjects will be randomized to six treatment sequences of 10 subjects each. Subjects will be admitted to the clinic on Day -1 before dosing. Each of the EVP-6124 and placebo treatment periods (blinded) will include a 10-day/9-night confinement to the Clinical Pharmacology Unit (CPU) with study drugs being administered on Day 1 and Day 2. The moxifloxacin treatment period (open-label) will include a 3-day/2-night confinement to the CPU with moxifloxacin administration on Day 1.

The study will include 2 washout periods in which each washout starts from the time of the last dose of the preceding treatment period to the first dose of the next treatment period. The washouts following the EVP-6124 or placebo treatments will be 30 days while the washout following the moxifloxacin treatment will be 7 days. Follow-up visit (5 to 10 days following discharge from the CPU).

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Nonsmokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc for 60 days prior to the administration of the study medication)
  • Physically and mentally healthy volunteers

Exclusion Criteria:

  • Clinically significant electrocardiographic abnormality in the opinion of the Investigator
  • History of cardiovascular abnormalities/conditions including syncope in the 3 months preceding enrollment or any history of significant previous cardiac arrhythmia;
  • Potassium levels outside of the normal ranges (3.5 to 5.2 mEq/L)
  • Clinically significant deviations from normal blood pressure (BP) as judged by the Investigator
  • Currently have, or have a history of, disease or dysfunction of the pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, or other body system, that is clinically significant in the opinion of the Investigator
  • Unwilling to refrain from strenuous exercise from 3 days prior to baseline Day -1 through discharge of each treatment period
  • Family history of Torsade de Pointes or long-QT syndrome, or cardiac death or sudden death without a preceding diagnosis of a condition that could be causative of sudden death
  • Evidence of any chronic medical condition requiring prescription medications
  • History of study drug allergy (including moxifloxacin, likely hypersensitivity or allergies to EVP-6124, or any components of EVP-6124)
  • Current or history of drug or alcohol abuse within the past year
  • Abnormal preadmission clinical laboratory evaluations which are considered clinically significant by the Principal Investigator
  • Any subject considering or scheduled to undergo any surgical procedure during the study
  • Acute illness within 7 days prior to study agent administration or have had a major illness or hospitalization within 1 month prior to study agent administration
  • Any subject who has received any known hepatic or renal clearance altering agents within 30 days prior to the first dose of study drug
  • A positive serology test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody at screening
  • A positive urine drug screen for ethanol or substances of abuse including cocaine,cannabinoids, phencyclidine, amphetamines, benzodiazepines, barbiturates, opiates, propoxyphene, and methadone at check-in(s)
  • Female subjects of childbearing potential with positive serum pregnancy test at screening or baseline (Day -1) of each treatment period. Sexually active females who refuse to take appropriate steps not to become pregnant during the course of the clinical study
  • Men, sexually active with female partners of childbearing potential, who are unwilling to use appropriate contraception during the course of the study and for 30 days after discharge from the last treatment period
  • Donated plasma or blood within 30 days prior to the first dose of study medication or has a history of blood donation of more than 450 mL within 3 months prior to dosing
  • Use of any prescription medications/products, within 14 days prior to dose administration on Day 1 of Treatment Period 1, unless deemed acceptable by the Investigator
  • Use of any over-the-counter, nonprescription preparations (including minerals, and phytotherapeutic/herbal/plant-derived preparations), within 14 days prior to dose administration on Day 1 of Treatment Period 1, with the exception of acetaminophen used at recommended doses
  • Use of investigational drug 30 days prior to Day -1 of Treatment Period 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT01487135     History of Changes
Other Study ID Numbers: EVP-6124-012
Study First Received: November 29, 2011
Last Updated: October 4, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by FORUM Pharmaceuticals Inc:
Thorough QT (TQT)
EVP-6124

Additional relevant MeSH terms:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2014